APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeting p53 Cancer Therapies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Targeting p53 Cancer Therapies Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchTargeting p53 Cancer Therapies Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeting p53 Cancer Therapies Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Targeting p53 Cancer Therapies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeting p53 Cancer Therapies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeting p53 Cancer Therapies Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Targeting p53 Cancer Therapies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeting p53 Cancer Therapies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Targeting p53 Cancer Therapies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Targeting p53 Cancer Therapies market include Alieron Therapeutics, Aprea Therapeutics, Kartos Therapeutics, MultiVir, Rain Oncology, SynerGene Therapeutics, Jc (Wuxi) Company, Sibiono GeneTech and Ascentage Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Targeting p53 Cancer Therapies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeting p53 Cancer Therapies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeting p53 Cancer Therapies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Targeting p53 Cancer Therapies market size, projected growth trends, production technologies, key applications, and end-use industries.

Targeting p53 Cancer Therapies Segment by Company

Alieron Therapeutics

Aprea Therapeutics

Kartos Therapeutics

MultiVir

Rain Oncology

SynerGene Therapeutics

Jc (Wuxi) Company

Sibiono GeneTech

Ascentage Pharma

Targeting p53 Cancer Therapies Segment by Type

Gene Therapy

Immunotherapy

Small Molecule Drugs

Others

Targeting p53 Cancer Therapies Segment by Application

Hospital

Clinic

Others

Targeting p53 Cancer Therapies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Targeting p53 Cancer Therapies status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Targeting p53 Cancer Therapies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Targeting p53 Cancer Therapies significant trends, drivers, influence factors in global and regions.

6. To analyze Targeting p53 Cancer Therapies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeting p53 Cancer Therapies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeting p53 Cancer Therapies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeting p53 Cancer Therapies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Targeting p53 Cancer Therapies market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeting p53 Cancer Therapies industry.

Chapter 3: Detailed analysis of Targeting p53 Cancer Therapies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Targeting p53 Cancer Therapies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Targeting p53 Cancer Therapies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Targeting p53 Cancer Therapies Industry Trends Table 2. Targeting p53 Cancer Therapies Industry Drivers Table 3. Targeting p53 Cancer Therapies Industry Opportunities and Challenges Table 4. Targeting p53 Cancer Therapies Industry Restraints Table 5. Global Targeting p53 Cancer Therapies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Targeting p53 Cancer Therapies Revenue Share by Company (2021-2026) Table 7. Global Targeting p53 Cancer Therapies Sales Volume by Company (k units) & (2021-2026) Table 8. Global Targeting p53 Cancer Therapies Sales Volume Share by Company (2021-2026) Table 9. Global Targeting p53 Cancer Therapies Average Price (US$/unit) of Company (2021-2026) Table 10. Global Targeting p53 Cancer Therapies Company Ranking, (2024-2026) & (USD Million) Table 11. Global Targeting p53 Cancer Therapies Key Company Manufacturing Base & Headquarters Table 12. Global Targeting p53 Cancer Therapies Company, Product Type & Application Table 13. Global Targeting p53 Cancer Therapies Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Targeting p53 Cancer Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Gene Therapy Table 18. Significant Companies of Immunotherapy Table 19. Significant Companies of Small Molecule Drugs Table 20. Significant Companies of Others Table 21. Global Targeting p53 Cancer Therapies Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Targeting p53 Cancer Therapies Sales Volume by Type (2021-2026) & (k units) Table 23. Global Targeting p53 Cancer Therapies Sales Volume by Type (2027-2032) & (k units) Table 24. Global Targeting p53 Cancer Therapies Sales Volume Share by Type (2021-2026) Table 25. Global Targeting p53 Cancer Therapies Sales Volume Share by Type (2027-2032) Table 26. Global Targeting p53 Cancer Therapies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Targeting p53 Cancer Therapies Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Targeting p53 Cancer Therapies Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Targeting p53 Cancer Therapies Sales Value Share by Type (2021-2026) Table 30. Global Targeting p53 Cancer Therapies Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Targeting p53 Cancer Therapies Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Targeting p53 Cancer Therapies Sales Volume by Application (2021-2026) & (k units) Table 36. Global Targeting p53 Cancer Therapies Sales Volume by Application (2027-2032) & (k units) Table 37. Global Targeting p53 Cancer Therapies Sales Volume Share by Application (2021-2026) Table 38. Global Targeting p53 Cancer Therapies Sales Volume Share by Application (2027-2032) Table 39. Global Targeting p53 Cancer Therapies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Targeting p53 Cancer Therapies Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Targeting p53 Cancer Therapies Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Targeting p53 Cancer Therapies Sales Value Share by Application (2021-2026) Table 43. Global Targeting p53 Cancer Therapies Sales Value Share by Application (2027-2032) Table 44. Global Targeting p53 Cancer Therapies Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Targeting p53 Cancer Therapies Sales by Region (2021-2026) & (k units) Table 46. Global Targeting p53 Cancer Therapies Sales Market Share by Region (2021-2026) Table 47. Global Targeting p53 Cancer Therapies Sales by Region (2027-2032) & (k units) Table 48. Global Targeting p53 Cancer Therapies Sales Market Share by Region (2027-2032) Table 49. Global Targeting p53 Cancer Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Targeting p53 Cancer Therapies Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Targeting p53 Cancer Therapies Sales Value Share by Region (2021-2026) Table 52. Global Targeting p53 Cancer Therapies Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Targeting p53 Cancer Therapies Sales Value Share by Region (2027-2032) Table 54. Global Targeting p53 Cancer Therapies Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Targeting p53 Cancer Therapies Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Targeting p53 Cancer Therapies Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Targeting p53 Cancer Therapies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Targeting p53 Cancer Therapies Sales by Country (2021-2026) & (k units) Table 59. Global Targeting p53 Cancer Therapies Sales Market Share by Country (2021-2026) Table 60. Global Targeting p53 Cancer Therapies Sales by Country (2027-2032) & (k units) Table 61. Global Targeting p53 Cancer Therapies Sales Market Share by Country (2027-2032) Table 62. Global Targeting p53 Cancer Therapies Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Targeting p53 Cancer Therapies Sales Value Market Share by Country (2021-2026) Table 64. Global Targeting p53 Cancer Therapies Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Targeting p53 Cancer Therapies Sales Value Market Share by Country (2027-2032) Table 66. Alieron Therapeutics Company Information Table 67. Alieron Therapeutics Business Overview Table 68. Alieron Therapeutics Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 70. Alieron Therapeutics Recent Development Table 71. Aprea Therapeutics Company Information Table 72. Aprea Therapeutics Business Overview Table 73. Aprea Therapeutics Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 75. Aprea Therapeutics Recent Development Table 76. Kartos Therapeutics Company Information Table 77. Kartos Therapeutics Business Overview Table 78. Kartos Therapeutics Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 80. Kartos Therapeutics Recent Development Table 81. MultiVir Company Information Table 82. MultiVir Business Overview Table 83. MultiVir Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. MultiVir Targeting p53 Cancer Therapies Product Portfolio Table 85. MultiVir Recent Development Table 86. Rain Oncology Company Information Table 87. Rain Oncology Business Overview Table 88. Rain Oncology Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Rain Oncology Targeting p53 Cancer Therapies Product Portfolio Table 90. Rain Oncology Recent Development Table 91. SynerGene Therapeutics Company Information Table 92. SynerGene Therapeutics Business Overview Table 93. SynerGene Therapeutics Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio Table 95. SynerGene Therapeutics Recent Development Table 96. Jc (Wuxi) Company Company Information Table 97. Jc (Wuxi) Company Business Overview Table 98. Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio Table 100. Jc (Wuxi) Company Recent Development Table 101. Sibiono GeneTech Company Information Table 102. Sibiono GeneTech Business Overview Table 103. Sibiono GeneTech Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio Table 105. Sibiono GeneTech Recent Development Table 106. Ascentage Pharma Company Information Table 107. Ascentage Pharma Business Overview Table 108. Ascentage Pharma Targeting p53 Cancer Therapies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio Table 110. Ascentage Pharma Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Targeting p53 Cancer Therapies Distributors List Table 114. Targeting p53 Cancer Therapies Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Targeting p53 Cancer Therapies Product Image Figure 2. Global Targeting p53 Cancer Therapies Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeting p53 Cancer Therapies Sales Value (2021-2032) & (US$ Million) Figure 4. Global Targeting p53 Cancer Therapies Sales (2021-2032) & (k units) Figure 5. Global Targeting p53 Cancer Therapies Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Targeting p53 Cancer Therapies Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Gene Therapy Image Figure 10. Immunotherapy Image Figure 11. Small Molecule Drugs Image Figure 12. Others Image Figure 13. Global Targeting p53 Cancer Therapies Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Targeting p53 Cancer Therapies Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Targeting p53 Cancer Therapies Sales Volume Share by Type (2021-2032) Figure 16. Global Targeting p53 Cancer Therapies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Targeting p53 Cancer Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Targeting p53 Cancer Therapies Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Targeting p53 Cancer Therapies Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Targeting p53 Cancer Therapies Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Targeting p53 Cancer Therapies Sales Volume Share by Application (2021-2032) Figure 25. Global Targeting p53 Cancer Therapies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Targeting p53 Cancer Therapies Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Targeting p53 Cancer Therapies Sales Value Share by Application (2021-2032) Figure 28. Global Targeting p53 Cancer Therapies Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Targeting p53 Cancer Therapies Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Targeting p53 Cancer Therapies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Targeting p53 Cancer Therapies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Targeting p53 Cancer Therapies Sales Value (2021-2032) & (US$ Million) Figure 33. North America Targeting p53 Cancer Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Targeting p53 Cancer Therapies Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Targeting p53 Cancer Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Targeting p53 Cancer Therapies Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Targeting p53 Cancer Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Targeting p53 Cancer Therapies Sales Value (2021-2032) & (US$ Million) Figure 39. South America Targeting p53 Cancer Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Targeting p53 Cancer Therapies Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Targeting p53 Cancer Therapies Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Targeting p53 Cancer Therapies Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Targeting p53 Cancer Therapies Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Gene Therapy
  • Immunotherapy
  • Small Molecule Drugs
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Alieron Therapeutics
  • Aprea Therapeutics
  • Kartos Therapeutics
  • MultiVir
  • Rain Oncology
  • SynerGene Therapeutics
  • Jc (Wuxi) Company
  • Sibiono GeneTech
  • Ascentage Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Targeting p53 Cancer Therapies Sales Value (2021-2032)
  4. 1.2.2 Global Targeting p53 Cancer Therapies Sales Volume (2021-2032)
  5. 1.2.3 Global Targeting p53 Cancer Therapies Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Targeting p53 Cancer Therapies Market Dynamics
  1. 2.1 Targeting p53 Cancer Therapies Industry Trends
  2. 2.2 Targeting p53 Cancer Therapies Industry Drivers
  3. 2.3 Targeting p53 Cancer Therapies Industry Opportunities and Challenges
  4. 2.4 Targeting p53 Cancer Therapies Industry Restraints
3 Targeting p53 Cancer Therapies Market by Company
  1. 3.1 Global Targeting p53 Cancer Therapies Company Revenue Ranking in 2025
  2. 3.2 Global Targeting p53 Cancer Therapies Revenue by Company (2021-2026)
  3. 3.3 Global Targeting p53 Cancer Therapies Sales Volume by Company (2021-2026)
  4. 3.4 Global Targeting p53 Cancer Therapies Average Price by Company (2021-2026)
  5. 3.5 Global Targeting p53 Cancer Therapies Company Ranking (2024-2026)
  6. 3.6 Global Targeting p53 Cancer Therapies Company Manufacturing Base and Headquarters
  7. 3.7 Global Targeting p53 Cancer Therapies Company Product Type and Application
  8. 3.8 Global Targeting p53 Cancer Therapies Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Targeting p53 Cancer Therapies Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Targeting p53 Cancer Therapies Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Targeting p53 Cancer Therapies Market by Type
  1. 4.1 Targeting p53 Cancer Therapies Type Introduction
  2. 4.1.1 Gene Therapy
  3. 4.1.2 Immunotherapy
  4. 4.1.3 Small Molecule Drugs
  5. 4.1.4 Others
  6. 4.2 Global Targeting p53 Cancer Therapies Sales Volume by Type
  7. 4.2.1 Global Targeting p53 Cancer Therapies Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Targeting p53 Cancer Therapies Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Targeting p53 Cancer Therapies Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Targeting p53 Cancer Therapies Sales Value by Type
  11. 4.3.1 Global Targeting p53 Cancer Therapies Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Targeting p53 Cancer Therapies Sales Value by Type (2021-2032)
  13. 4.3.3 Global Targeting p53 Cancer Therapies Sales Value Share by Type (2021-2032)
5 Targeting p53 Cancer Therapies Market by Application
  1. 5.1 Targeting p53 Cancer Therapies Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Targeting p53 Cancer Therapies Sales Volume by Application
  6. 5.2.1 Global Targeting p53 Cancer Therapies Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Targeting p53 Cancer Therapies Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Targeting p53 Cancer Therapies Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Targeting p53 Cancer Therapies Sales Value by Application
  10. 5.3.1 Global Targeting p53 Cancer Therapies Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Targeting p53 Cancer Therapies Sales Value by Application (2021-2032)
  12. 5.3.3 Global Targeting p53 Cancer Therapies Sales Value Share by Application (2021-2032)
6 Targeting p53 Cancer Therapies Regional Sales and Value Analysis
  1. 6.1 Global Targeting p53 Cancer Therapies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeting p53 Cancer Therapies Sales by Region (2021-2032)
  3. 6.2.1 Global Targeting p53 Cancer Therapies Sales by Region: 2021-2026
  4. 6.2.2 Global Targeting p53 Cancer Therapies Sales by Region (2027-2032)
  5. 6.3 Global Targeting p53 Cancer Therapies Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Targeting p53 Cancer Therapies Sales Value by Region (2021-2032)
  7. 6.4.1 Global Targeting p53 Cancer Therapies Sales Value by Region: 2021-2026
  8. 6.4.2 Global Targeting p53 Cancer Therapies Sales Value by Region (2027-2032)
  9. 6.5 Global Targeting p53 Cancer Therapies Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Targeting p53 Cancer Therapies Sales Value (2021-2032)
  12. 6.6.2 North America Targeting p53 Cancer Therapies Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Targeting p53 Cancer Therapies Sales Value (2021-2032)
  15. 6.7.2 Europe Targeting p53 Cancer Therapies Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Targeting p53 Cancer Therapies Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Targeting p53 Cancer Therapies Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Targeting p53 Cancer Therapies Sales Value (2021-2032)
  21. 6.9.2 South America Targeting p53 Cancer Therapies Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Targeting p53 Cancer Therapies Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Targeting p53 Cancer Therapies Sales Value Share by Country, 2025 VS 2032
7 Targeting p53 Cancer Therapies Country-level Sales and Value Analysis
  1. 7.1 Global Targeting p53 Cancer Therapies Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Targeting p53 Cancer Therapies Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Targeting p53 Cancer Therapies Sales by Country (2021-2032)
  4. 7.3.1 Global Targeting p53 Cancer Therapies Sales by Country (2021-2026)
  5. 7.3.2 Global Targeting p53 Cancer Therapies Sales by Country (2027-2032)
  6. 7.4 Global Targeting p53 Cancer Therapies Sales Value by Country (2021-2032)
  7. 7.4.1 Global Targeting p53 Cancer Therapies Sales Value by Country (2021-2026)
  8. 7.4.2 Global Targeting p53 Cancer Therapies Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Targeting p53 Cancer Therapies Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Targeting p53 Cancer Therapies Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Targeting p53 Cancer Therapies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alieron Therapeutics
  2. 8.1.1 Alieron Therapeutics Company Information
  3. 8.1.2 Alieron Therapeutics Business Overview
  4. 8.1.3 Alieron Therapeutics Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alieron Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  6. 8.1.5 Alieron Therapeutics Recent Developments
  7. 8.2 Aprea Therapeutics
  8. 8.2.1 Aprea Therapeutics Company Information
  9. 8.2.2 Aprea Therapeutics Business Overview
  10. 8.2.3 Aprea Therapeutics Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aprea Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  12. 8.2.5 Aprea Therapeutics Recent Developments
  13. 8.3 Kartos Therapeutics
  14. 8.3.1 Kartos Therapeutics Company Information
  15. 8.3.2 Kartos Therapeutics Business Overview
  16. 8.3.3 Kartos Therapeutics Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Kartos Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  18. 8.3.5 Kartos Therapeutics Recent Developments
  19. 8.4 MultiVir
  20. 8.4.1 MultiVir Company Information
  21. 8.4.2 MultiVir Business Overview
  22. 8.4.3 MultiVir Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MultiVir Targeting p53 Cancer Therapies Product Portfolio
  24. 8.4.5 MultiVir Recent Developments
  25. 8.5 Rain Oncology
  26. 8.5.1 Rain Oncology Company Information
  27. 8.5.2 Rain Oncology Business Overview
  28. 8.5.3 Rain Oncology Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Rain Oncology Targeting p53 Cancer Therapies Product Portfolio
  30. 8.5.5 Rain Oncology Recent Developments
  31. 8.6 SynerGene Therapeutics
  32. 8.6.1 SynerGene Therapeutics Company Information
  33. 8.6.2 SynerGene Therapeutics Business Overview
  34. 8.6.3 SynerGene Therapeutics Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 SynerGene Therapeutics Targeting p53 Cancer Therapies Product Portfolio
  36. 8.6.5 SynerGene Therapeutics Recent Developments
  37. 8.7 Jc (Wuxi) Company
  38. 8.7.1 Jc (Wuxi) Company Company Information
  39. 8.7.2 Jc (Wuxi) Company Business Overview
  40. 8.7.3 Jc (Wuxi) Company Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jc (Wuxi) Company Targeting p53 Cancer Therapies Product Portfolio
  42. 8.7.5 Jc (Wuxi) Company Recent Developments
  43. 8.8 Sibiono GeneTech
  44. 8.8.1 Sibiono GeneTech Company Information
  45. 8.8.2 Sibiono GeneTech Business Overview
  46. 8.8.3 Sibiono GeneTech Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sibiono GeneTech Targeting p53 Cancer Therapies Product Portfolio
  48. 8.8.5 Sibiono GeneTech Recent Developments
  49. 8.9 Ascentage Pharma
  50. 8.9.1 Ascentage Pharma Company Information
  51. 8.9.2 Ascentage Pharma Business Overview
  52. 8.9.3 Ascentage Pharma Targeting p53 Cancer Therapies Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Ascentage Pharma Targeting p53 Cancer Therapies Product Portfolio
  54. 8.9.5 Ascentage Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Targeting p53 Cancer Therapies Value Chain Analysis
  2. 9.1.1 Targeting p53 Cancer Therapies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Targeting p53 Cancer Therapies Sales Mode & Process
  6. 9.2 Targeting p53 Cancer Therapies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Targeting p53 Cancer Therapies Distributors
  9. 9.2.3 Targeting p53 Cancer Therapies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst